BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

• Published in: NPJ precision oncology 2023-02, Vol.7 (1), p.19-19, Article 19
• Main Authors: Nelson, Blessie Elizabeth, Roszik, Jason, Janku, Filip, Hong, David S., Kato, Shumei, Naing, Aung, Piha-Paul, Sarina, Fu, Siqing, Tsimberidou, Apostolia, Cabanillas, Maria, Busaidy, Naifa Lamki, Javle, Milind, Byers, Lauren Averett, Heymach, John V., Meric-Bernstam, Funda, Subbiah, Vivek
• Format: Article
• Language: English
• Subjects: 631/67/1059/153; 692/4028/67/1059/602; 692/699/67/69; Cancer Research; Chemotherapy; Gene Therapy; Human Genetics; Inhibitor drugs; Internal Medicine; Medicine; Medicine & Public Health; Mutation; Oncology; Targeted cancer therapy; Tumors
• ISSN: 2397-768X; 2397-768X
• DOI: 10.1038/s41698-022-00341-0

Combined BRAF + MEK inhibition is FDA approved for BRAF V600E-mutant solid tumors except for colorectal cancer. However, beyond MAPK mediated resistance several other mechanisms of resistance such as activation of CRAF, ARAF, MET, P13K/AKT/mTOR pathway exist among other complex pathways. In the VEM-PLUS study, we performed a pooled analysis of four phase one studies evaluating the safety and efficacy of vemurafenib monotherapy and vemurafenib combined with targeted therapies (sorafenib, crizotinib, or everolimus) or carboplatin plus paclitaxel in advanced solid tumors harboring BRAF V600 mutations. When vemurafenib monotherapy was compared with the combination regimens, no significant differences in OS or PFS durations were noted, except for inferior OS in the vemurafenib and paclitaxel and carboplatin trial ( P  = 0.011; HR, 2.4; 95% CI, 1.22–4.7) and in crossover patients ( P  = 0.0025; HR, 2.089; 95% CI, 1.2–3.4). Patients naïve to prior BRAF inhibitors had statistically significantly improved OS at 12.6 months compared to 10.4 months in the BRAF therapy refractory group ( P  = 0.024; HR, 1.69; 95% CI 1.07–2.68). The median PFS was statistically significant between both groups, with 7 months in the BRAF therapy naïve group compared to 4.7 months in the BRAF therapy refractory group ( P  = 0.016; HR, 1.80; 95% CI 1.11–2.91). The confirmed ORR in the vemurafenib monotherapy trial (28%) was higher than that in the combination trials. Our findings suggest that, compared with vemurafenib monotherapy, combinations of vemurafenib with cytotoxic chemotherapy or with RAF- or mTOR-targeting agents do not significantly extend the OS or PFS of patients who have solid tumors with BRAF V600E mutations. Gaining a better understanding of the molecular mechanisms of BRAF inhibitor resistance, balancing toxicity and efficacy with novel trial designs are warranted.